Mindstate Design Labs vs Amgen

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amgen leads in AI visibility (88 vs 38)
Mindstate Design Labs logo

Mindstate Design Labs

EmergingHealthcare

General

Non-hallucinogenic psychedelic drug developer using AI to design therapeutics without dissociation; $25.5M raised backed by OpenAI/Neuralink founders with FDA Phase I approval for MSD-001 in 2024.

AI VisibilityBeta
Overall Score
D38
Category Rank
#444 of 596
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
34
Gemini
37

About

Mindstate Design Labs is a Los Angeles-based clinical-stage biotech developing non-hallucinogenic psychedelic therapeutics — using computational neuroscience and machine learning to engineer psychedelic-inspired molecules that activate the neural mechanisms associated with therapeutic benefit (neuroplasticity, serotonin receptor modulation) while minimizing or eliminating the dissociative hallucinogenic effects that limit psychedelic therapy to clinical settings. A Y Combinator W21 graduate, Mindstate raised $25.5 million total, achieved $1.3 million in revenue in 2024 with a 19-person team, and received FDA and EMA approval for Phase I human trials of lead program MSD-001 in 2024, backed by founders of OpenAI, Neuralink, Coinbase, and Initialized Capital.

Full profile
Amgen logo

Amgen

LeaderHealthcare Tech

AI Drug Discovery

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

AI VisibilityBeta
Overall Score
A88
Category Rank
#3 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
87
Gemini
85

About

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Full profile

AI Visibility Head-to-Head

38
Overall Score
88
#444
Category Rank
#3
90
AI Consensus
78
stable
Trend
stable
34
ChatGPT
83
34
Perplexity
87
37
Gemini
85
33
Claude
90
35
Grok
92

Key Details

Category
General
AI Drug Discovery
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Amgen
AI Drug Discovery

Integrations

Amgen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.